Nimodipine Dispersible Tablets

Nimodipine is a Ca2 channel blocker. Under normal circumstances, the contraction of smooth muscle depends on the entry of Ca2 into the cell, causing the depolarization of the transmembrane current. Nimodipine achieves the purpose of relieving vasospasm by effectively preventing Ca2 from entering the cell and inhibiting the contraction of smooth muscle. Animal experiments have shown that the effect of nimodipine on cerebral arteries is much stronger than that on arteries in other parts of the body, and because it has a high lipophilic characteristic, it is easy to pass through the blood-brain barrier. When used for the treatment of subarachnoid hemorrhage, the concentration in cerebrospinal fluid can reach 12.5ng/ml. It can be inferred that it can be used clinically to prevent vasospasm after subarachnoid hemorrhage, but the mechanism of action of this drug in human application is still unclear. In addition, it also has the effect of protecting and promoting memory and promoting intellectual recovery. Therefore, it can selectively act on cerebral vascular smooth muscle, dilate cerebral blood vessels, increase cerebral blood flow, and significantly reduce ischemic brain damage caused by vasospasm.

The main ingredient of this product is nimodipine. Its chemical name is (plusmn;) isopropyl-2-methoxyethyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate. Molecular formula: C21H26N2O7, molecular weight: 418.45.

Yellow tablets.

It is suitable for improving blood circulation in the recovery period of cerebral vasospasm after subarachnoid hemorrhage of various reasons and acute cerebrovascular disease.

Oral administration: During the recovery period of acute cerebrovascular disease, 30-40 mg at a time, 4 times a day, or once every 4 hours.

A large number of clinical practices have shown that about 11.2% of patients with subarachnoid hemorrhage experience adverse reactions when treated with nimodipine. The most common adverse reactions are: 1. Decreased blood pressure, the degree of which is related to the drug dose. 2. Hepatitis. 3. Skin tingling. 4. Gastrointestinal bleeding. 5. Thrombocytopenia. 6. Occasionally transient dizziness, headache, facial flushing, vomiting, gastrointestinal discomfort, etc. In addition, after oral administration of nimodipine, some patients may experience an increase in alkaline phosphatase (ALP), lactate dehydrogenase (LDH), increased blood sugar, and an increase in platelet count in some individuals.

Patients with severe liver damage are contraindicated. It is not recommended to take nimodipine and anti-epileptic drugs at the same time. The drug can be secreted by breast milk and should not be used by breastfeeding women.

Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: The drug can be secreted by breast milk, so it is not suitable for lactating women. Animal experiments indicate that this product is teratogenic. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference.

1. When used in combination with other calcium ion antagonists that act on the cardiovascular system, it can increase the effectiveness of other calcium ion antagonists. 2. When nimodipine 90 mg/day is used in combination with cimetidine 1000 mg/day for more than one week, the blood concentration of nimodipine can increase by 50%, which may be related to the inhibition of nimodipine metabolism by cimetidine in the liver cytochrome P450.

Store in a cool, dry and ventilated place.

20mg

24 months

Jinhua Enterprise (Group) Co., Ltd. Xi'an Jinhua Pharmaceutical Factory

• Founded in:

  1997-11-05

• Address:

  No. 202, Keji 4th Road, High-tech Industrial Development Zone, Xi'an High-tech Zone

• Tax NO.:

  9161000092056049XF

• Registered Funds:

  -

• Website:

  Log in to view

• Email:

  Log in to view